Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options 
Maxion Therapeutics Appoints Joel Edwards as Chief Business Officer
Cambridge, UK, 1 October 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G...
Primary.Health Launches Nation’s First Advanced Newborn Screening Case Management Platform
Primary’s cloud-based system modernizes state newborn screening tracking and follow-up, incorporating cutting-edge science, evidence-based clinical protocols, and emerging screening methodologies...
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting...
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical...
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc....
Alignment Health Unveils 2026 Medicare Advantage Plans with Strong Benefits, Expanded Support for Seniors
Plans to reach nearly 8.3 million Medicare-eligible adults across five states during annual enrollment period, Oct. 15-Dec. 7ORANGE, Calif., Oct....
Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025
PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with...
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company...
Avalyn Appoints Industry Veterans Jill Denning and Kimberley Cummings to Leadership
Appointments expand clinical and regulatory capabilities ahead of key program milestonesBOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc.,...
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty...
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
CHICAGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for...
CorVista Health Appoints Guido Neels and Dino Trevisani to Board of Directors
Veteran MedTech leader Guido Neels joins CorVista, leveraging his experience as EW Healthcare Partners Operating Partner and former Guidant COO.Company...
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead...
Stryker to announce financial results for its third quarter of fiscal year 2025
Portage, Michigan, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its third...
ATMA CENA Grows National Mental Health Network to 13 Clinics
Expanding access to safe, regulated psychedelic-assisted therapy across Canada CALGARY, Alberta, Oct. 01, 2025 (GLOBE NEWSWIRE) -- ATMA CENA, a...
Solid Biosciences to Present at Upcoming Scientific Meetings
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic...
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19
- Meeting date aligns with prior guidance - - FDA to review AEON’s analytical development plan and initial data -...